...ing a panic disorder may benefit more from treatme...ication instead // of the care usually offered by ...bling and costly anxiety disorders. In the study, ...nic disorder were randomly assigned to receive tre...
...t forgotten the thalidomide tragedy thalidomide in...tment of morning sickness // to pregnant mothers a.... Now, doctors see a new future use for the infamo...maintain their weight. The effects of this drug we...
...dy in Journal of Dental Research, caries in primar...nt teeth.// A primary tooth can have caries for a...alth or history, socio-economic status, years of e...ce to primary teeth, and early loss of primary tee...
...e of Journal of American Medical Association, rese...growing// trend in delaying the vaccination schedu...of the vaccinated diseases affecting the children....of the vaccines that need to be completed during t...
Other Medicine News:(Date:11/20/2008)...ewswire/ -- The following is being released by Cen...AT: World AIDS Day Audio Media Conference , ... 11:00 a.m. EST , Call-in number: 1-800-949-847...talk.com/r/1xe41i2yre8rs , , WHY: With n...ewly put on treatment worldwide, advocates are cal...
(Date:11/20/2008)...A, Nov. 20 GlaxoSmithKlin...tates Food and Drug Administration (FDA) granted a...for the treatment of thrombocytopenia in patients ...purpura (ITP) who have had an insufficient respons...my. The approval is a significant milestone for PR...
(Date:11/20/2008)...20 Arpida (SWX:,ARPN) a...ory Committee of the,U.S. Food and Drug Administr...l of intravenous iclaprim, an antibiotic currently...h complicated skin and skin structure infections,...sistant Staphylococcus,aureus (MRSA). , Ar...
(Date:11/20/2008)...wire-FirstCall/ -- Bionovo, Inc.,(Nasdaq: BNVI ...the Phase 1B,clinical trial of their lead drug ca...L101, at the Society for Integrative Oncology,s Fi... The Company,s oral presentation was selected,as... part of the Best of the,SIO Session on November ...
Breaking Medicine Technology:Faith and Civil Society Leaders Call for Truth and Leadership in U.S. HIV Prevention Efforts 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5New surgery improves head and neck cancer treatment 3113 1New surgery improves head and neck cancer treatment 3113 2Too Few Cancer Survivors Pursue Healthy Lifestyles 18009 1Too Few Cancer Survivors Pursue Healthy Lifestyles 18009 2Too Few Cancer Survivors Pursue Healthy Lifestyles 18009 3Media Alert 3A 100 Black Men of Atlanta Host 3rd Annual Community Health Fair 18006 1Media Alert 3A 100 Black Men of Atlanta Host 3rd Annual Community Health Fair 18006 2InfoLogix Announces First Quarter 2008 Financial Results 18003 1InfoLogix Announces First Quarter 2008 Financial Results 18003 2InfoLogix Announces First Quarter 2008 Financial Results 18003 3InfoLogix Announces First Quarter 2008 Financial Results 18003 4InfoLogix Announces First Quarter 2008 Financial Results 18003 5InfoLogix Announces First Quarter 2008 Financial Results 18003 6InfoLogix Announces First Quarter 2008 Financial Results 18003 7InfoLogix Announces First Quarter 2008 Financial Results 18003 8InfoLogix Announces First Quarter 2008 Financial Results 18003 9... MARKHAM, ON, June 28, 2007 /PRNewswire/ - Cytoch...se I clinical trial of,CTA018 Injection. The initi...A018 was safe and well tolerated. Complete study,r... completed Phase I trial was an open label,placeb...,administered to 20 healthy volunteers. In this tr...
... WORCESTER, Mass.--(BUSINESS WIRE)--Jun 28, 2007 -...rity owned subsidiary of,Accentia Biopharmaceutica... blinded interim data from the start of its fast-t...TM) for Non-Hodgkin,s,lymphoma (NHL) from Septembe...a is the most recent data that has been made avail...
Other Medicine Technology:Cytochroma Reports Positive Phase I Clinical Data for CTA018,Injection 2Cytochroma Reports Positive Phase I Clinical Data for CTA018,Injection 3Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 2Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 3Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 4Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 5...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: